CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Executive Employment Agreement • March 21st, 2024 • Pyxis Oncology, Inc. • Pharmaceutical preparations
This Agreement supersedes, amends, and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein.
CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Dissolution Agreement • March 21st, 2024 • Pyxis Oncology, Inc. • Pharmaceutical preparations • Delaware
THIS DISSOLUTION AGREEMENT (the “Agreement”) is entered into effective as of February 6, 2024 (“Effective Date”), by and among Voxall Therapeutics, LLC (formerly Kyma Therapeutics, LLC) (“VOX”), Pyxis Oncology, Inc. (“PYXS”) and Alloy Therapeutics, Inc. (“ATX”, each VOX, PYXS, and ATX, individually a “Party” and collectively the “Parties”).
